RxDoctor Payments Data

Magdalena Shuler, PhD

Retina Specialist · Panama City, FLNPI 1851368559

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $24,975 of the $29,060 with a category attached, or 85.9%. US Retina LLC accounts for 85.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $10,029 and has fallen 92.1% since, to $793 in 2025.

$29,060in general payments, 2019–2025

Across 147 payments — averaging $197.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$25K
  • Genentech USA, Inc.$962
  • AbbVie$585
  • Alimera Sciences, Inc.$543
  • Apellis Pharmaceuticals, Inc.$500
  • Regeneron Healthcare Solutions, Inc.$401
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$4,04714%
  • Gifts$390%
  • Ownership interest$24,97586%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,060 in reported general payments places this provider in the 85th percentile of 118 retina specialist providers in Florida.

See all retina specialist providers in Florida

Medicare billing

Part B allowed, 2024
$2,784,974
Medicare patients
833
Services billed
18,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tobramycin-DexamethasoneTobramycin/Dexamethasone75$3,902
CombiganBrimonidine Tartrate/Timolol14$3,335
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$3,158
Prednisolone Acetate41$2,713
Ofloxacin40$457
Timolol Maleate12$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan$585$3,33514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 118 retina specialist providers in Florida.

Other retina specialist in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →